# US 2015/0105561 A1 · Process for the preparation of bendamustine hydrochloride

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2015/0105561 A1
- Document ID: US20150105561A1
- Status: Published application
- Kind: A1
- Application number: 14/576,594
- Filed: 2014-12-19
- Published: 2015-04-16
- Earliest claimed: 2011-09-26
- Assignees: Fresenius Kabi Oncology Limited
- Applicants: Fresenius Kabi Oncology Limited
- Inventors: Bhuwan Bhaskar Mishra; Nikunj Shambhubhai Kachhadia; Vinod Singh Tomar; Saswata Lahiri
- Web page: https://patentgrep.com/patent/US20150105561A1

## CPC

- C07D 235/16: Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
- A61P 35/00: Antineoplastic agents
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)
- A61P: SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

## Abstract

The present invention relates to an improved process for the synthesis of bendamustine, in particular, bendamustine hydrochloride of the formula (VI) and its intermediate 1-methyl-5-[bis(2-chloroethyl)amino]-1H-benzimidazol-2-yl]lithium butanoate of formula (V), both having a purity of ≧99%, which is simple, convenient, economical, does not use hazardous chemicals and is industrially viable.

## Claims

### Claim at position 1

-38. (canceled)

### Claim 39

The lithium salt of 4-[1-methyl-5-bis-(2-chloroethyl)-benzimidazolyl-2]butyric acid of formula (V)

### Claim 40

A process for preparing a lithium salt of 4-[1-methyl-5-bis-(2-chloroethyl)-benzimidazolyl-2]butyric acid of formula (V)
comprising hydrolyzing the compound of formula (IV), wherein R is C1-C6 alkyl,
with a lithium source in the presence of a solvent.

### Claim 41 (depends on 40)

The process according to claim 40, wherein the lithium source is selected from the group consisting of lithium hydroxide hydrate, lithium carbonate and lithium hydride.

### Claim 42 (depends on 40)

The process according to claim 40, wherein the lithium source is lithium hydroxide hydrate.

### Claim 43 (depends on 40)

The process according to claim 40, wherein hydrolysis of the compound of formula (IV) is carried out in the presence of lithium hydroxide hydrate in water.

### Claim 44 (depends on 40)

The process according to claim 40, wherein the solvent is selected from the group consisting of water, acetone, methyl ethyl ketone, isobutyl ketone, acetonitrile, propionitrile, methanol, ethanol, isopropanol, methylene chloride, ethylenedichloride, dimethylsulfoxide, dimethylformamide, ethyl acetate, isopropyl acetate, dioxane, tetrahydrofuran, and mixtures thereof.

### Claim 45 (depends on 40)

The process according to claim 40, wherein the solvent is acetone or a mixture of acetone and water.

### Claim 46 (depends on 40)

The process according to claim 40, further comprising converting the compound of formula (V) into bendamustine or bendamustine hydrochloride of formula (VI)

### Claim 47 (depends on 46)

The process according to claim 46, wherein the conversion of the compound of formula (V) to bendamustine or bendamustine hydrochloride of formula (VI) is carried out in the presence of hydrochloric acid.

### Claim 48 (depends on 47)

The process according to claim 47, wherein the purity of bendamustine hydrochloride of formula (VI) is greater than 99.5%.
